Source: FDA, National Drug Code (US) Revision Year: 2020
ZEPOSIA contains ozanimod, a S1P receptor modulator and is supplied as ozanimod hydrochloride (HCl).
The chemical name of ozanimod HCl is 5-(3-{(1S)1[(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-4-yl}-1,2,4-oxadiazol-5-yl)2[(propan-2-yl)oxy]benzonitrile, monohydrochloride.
Ozanimod HCl is a white to off-white solid that is freely soluble in water and alcohol with a molecular weight of 440.92 g/mol.
The chemical structure is:
ZEPOSIA capsules are provided as hard gelatin capsules for oral administration, containing 0.23, 0.46, or 0.92 mg of ozanimod, equivalent to 0.25, 0.5, and 1 mg ozanimod HCl, respectively. ZEPOSIA capsules consist of the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The capsule shell, imprinted with black ink, contains the following inactive ingredients: black iron oxide, gelatin, red iron oxide, titanium dioxide, and yellow iron oxide.
Dosage Forms and Strengths |
---|
ZEPOSIA is available as capsules in the following dosage strengths:
|
How Supplied | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ZEPOSIA is available as capsules in the following dosage strengths:
Capsules are supplied in the following strengths and package configurations:
|
Drug | Countries | |
---|---|---|
ZEPOSIA | Austria, Australia, Canada, Estonia, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.